We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In parallel with the Phase 1 clinical trial, the Company plans to publish a comprehensive literature review of Danon cases and conduct a retrospective chart review. In addition, the Company will initiate a prospective natural history study with enrollment
The FDA has expanded the clearance of NuVasive’s limb-lengthening system to include bone transport, a method that allows an orthopedic surgeon to regenerate bony tissue to fill a space where bone is missing.